Social Pulse: Eli Lilly and Co (LLY.N)
LLY.N on New York Stock Exchange
24 Oct 2014
24 Oct 2014
Price Change (% chg)
- ModernGraham Quarterly Valuation Of Eli Lilly & Co.
- Eli Lilly and's (LLY) CEO John Lechleiter on Q3 2014 Results - Earnings Call Transcript
- Eli Lilly Hit By Patent Expirations, Prescription Volume Plunges
- How Will Eli Lilly (LLY) Stock Be Affected Today By Its Mixed Earnings Report?
- Eli Lilly and (LLY) Q3 2014 Results - Earnings Call Webcast
- Stock Market Today: Stocks Surge as Caterpillar and GM Top Estimates
- Analyst Opinion on Eli Lilly & Co. and Pfizer Inc. -- Drug Manufacturers Countering Patent Expirations with New Products
- Market Influences That Drive Equities Forward -- Industry Report on Eli Lilly And Company and Stericycle, Inc.
- A Refreshing Outlook - Consensus Reports on Arena Pharmaceuticals, Inc. and Eli Lilly and Company
- Where We Are Headed -- New Outlook on Eli Lilly and Company and Arena Pharmaceuticals, Inc.
- FDA Approves ERBITUX(R) (cetuximab) as First-Line Treatment in KRAS Mutation-Negative (Wild-Type) Epidermal Growth Factor Receptor (EGFR)-Expressing Metastatic Colorectal Cancer in Combination with FOLFIRI (Irinotecan, 5-Flu